Denali Therapeutics Inc (NAS:DNLI)
$ 20.61 -0.71 (-3.33%) Market Cap: 2.97 Bil Enterprise Value: 2.28 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 57/100

Denali Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript

May 24, 2021 / 06:00PM GMT
Release Date Price: $61.54 (+4.48%)
Esther P. Rajavelu
UBS Investment Bank, Research Division - Analyst & Executive Director

Good day, everyone, and thank you for joining us at the Virtual UBS Healthcare Conference on our fireside chat with the Denali management team.

I am Esther Rajavelu covering SMID cap biotech here at UBS, and joining me today are Ryan Watts, CEO; and Carole Ho, Chief Medical Officer of Denali. Thank you both for your time. We are excited to have you join us.

Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

Esther, thank you so much. Really great to be here. Looking forward to discussing Denali and really appreciate your interest in our approach to defeating degeneration.

Esther P. Rajavelu;Ryan J. Watts
UBS Investment Bank, Research Division - Analyst & Executive Director;

Great. So Ryan perhaps you can start us off with a brief overview of what you're most excited about as you look at the next, I don't know, 6 to 12 to 18 months for Denali.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot